Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share

v3.22.2.2
Earnings Per Share
3 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Earnings Per Share

Note 9. Earnings Per Share:

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

    

Quarter Ended

September 30, 

    

2022

    

2021

Earnings per share – basic:

Net earnings, including noncontrolling interest

$

89,734

 

$

68,981

Less net earnings (loss) attributable to noncontrolling interest

179

 

(634)

Net earnings attributable to Bio-Techne

$

89,555

$

69,615

Income allocated to participating securities

 

(26)

 

(36)

Income available to common shareholders

$

89,529

$

69,579

Weighted-average shares outstanding – basic

 

39,232

 

39,094

Earnings per share – basic

$

2.28

$

1.78

Earnings per share – diluted:

 

  

 

  

Net earnings, including noncontrolling interest

$

89,734

$

68,981

Less net earnings (loss) attributable to noncontrolling interest

179

(634)

Net earnings attributable to Bio-Techne

$

89,555

$

69,615

Income allocated to participating securities

 

(26)

 

(36)

Income available to common shareholders

$

89,529

$

69,579

Weighted-average shares outstanding – basic

 

39,232

 

39,094

Dilutive effect of stock options and restricted stock units

 

1,311

 

2,064

Weighted-average common shares outstanding – diluted

 

40,543

 

41,158

Earnings per share – diluted

$

2.21

$

1.69

The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 1.1 million and 0.4 million for the quarter ended September 30, 2022 and 2021, respectively.